Pomanda estimates the enterprise value of INTRACT PHARMA LIMITED at £466k based on a Turnover of £349.4k and 1.33x industry multiple (adjusted for size and gross margin).
intract pharma limitedEstimated Valuation
£0
Pomanda estimates the enterprise value of INTRACT PHARMA LIMITED at £0 based on an EBITDA of £-354.4k and a 5.26x industry multiple (adjusted for size and gross margin).
intract pharma limitedEstimated Valuation
£530k
Pomanda estimates the enterprise value of INTRACT PHARMA LIMITED at £530k based on Net Assets of £295.9k and 1.79x industry multiple (adjusted for liquidity).
Edit your figures and get a professional valuation report.
Intract Pharma LimitedOverview
Intract Pharma Limited is a live company located in cambridge, CB22 5EG with a Companies House number of 09610219. It operates in the research and experimental development on biotechnology sector, SIC Code 72110. Founded in May 2015, it's largest shareholder is
abdul basit
with a 59% stake. Intract Pharma Limited is a established,
micro sized company, Pomanda has estimated its turnover at
£349.4k with
declining
growth in recent years.
Pomanda's financial health check has awarded Intract Pharma Limited a 3.5 rating. We use a traffic light system to show it exceeds the industry average on 3 measures and has 5 areas for improvement. Company Health Check FAQs
Health Rating3.5out of 5
3 Strong
3 Regular
5 Weak
Size
annual sales of £349.4k, make it smaller than the average company (£3.9m)
£349.4k - Intract Pharma Limited
£3.9m - Industry AVG
Growth
3 year (CAGR) sales growth of -30%, show it is growing at a slower rate (13.2%)
-30% - Intract Pharma Limited
13.2% - Industry AVG
Production
with a gross margin of 55.7%, this company has a comparable cost of product (55.7%)
55.7% - Intract Pharma Limited
55.7% - Industry AVG
Profitability
an operating margin of -110.8% make it less profitable than the average company (-6.3%)
-110.8% - Intract Pharma Limited
-6.3% - Industry AVG
Employees
with 6 employees, this is below the industry average (47)
6 - Intract Pharma Limited
47 - Industry AVG
Pay Structure
on an average salary of £82.4k, the company has an equivalent pay structure (£82.4k)
£82.4k - Intract Pharma Limited
£82.4k - Industry AVG
Efficiency
resulting in sales per employee of £58.2k, this is less efficient (£130.9k)
£58.2k - Intract Pharma Limited
£130.9k - Industry AVG
Debtor Days
it gets paid by customers after 0 days, this is earlier than average (54 days)
0 days - Intract Pharma Limited
54 days - Industry AVG
Creditor Days
its suppliers are paid after 59 days, this is close to average (57 days)
59 days - Intract Pharma Limited
57 days - Industry AVG
Stock Days
There is insufficient data available for this Key Performance Indicator!
- - Intract Pharma Limited
- - Industry AVG
Cash Balance
has cash to cover current liabilities
for 324 weeks, this is more cash available to meet short term requirements (33 weeks)
324 weeks - Intract Pharma Limited
33 weeks - Industry AVG
Debt Level
it has a ratio of liabilities to total assets of 11.3%, this is a lower level of debt than the average (50.6%)
11.3% - Intract Pharma Limited
50.6% - Industry AVG
INTRACT PHARMA LIMITED financials
EXPORT
Intract Pharma Limited's latest turnover from May 2024 is estimated at £349.4 thousand and the company has net assets of £295.9 thousand. According to their latest financial statements, Intract Pharma Limited has 6 employees and maintains cash reserves of £235.9 thousand as reported in the balance sheet.
Data source:Companies House, Pomanda Estimates
May 2024
May 2023
May 2022
May 2021
May 2020
May 2019
May 2018
May 2017
May 2016
Turnover
349,400
477,869
637,277
1,036,736
603,285
941,950
371,360
2,356,091
4,685,277
Other Income Or Grants
Cost Of Sales
154,936
216,625
313,414
501,259
291,450
450,097
175,197
1,124,107
2,529,022
Gross Profit
194,463
261,244
323,863
535,477
311,835
491,852
196,163
1,231,985
2,156,254
Admin Expenses
581,644
287,647
597,824
606,321
49,776
728,637
1,083,000
1,313,337
932,800
Operating Profit
-387,181
-26,403
-273,961
-70,844
262,059
-236,785
-886,837
-81,352
1,223,454
Interest Payable
Interest Receivable
20,546
23,353
4,885
613
501
4,258
2,183
Pre-Tax Profit
-366,635
-3,050
-269,076
-70,231
262,560
-232,527
-884,654
-81,352
1,223,454
Tax
-49,886
-244,691
Profit After Tax
-366,635
-3,050
-269,076
-70,231
212,674
-232,527
-884,654
-81,352
978,763
Dividends Paid
Retained Profit
-366,635
-3,050
-269,076
-70,231
212,674
-232,527
-884,654
-81,352
978,763
Employee Costs
494,544
534,263
591,474
628,875
679,447
668,621
438,626
232,253
2,674,601
Number Of Employees
6
7
8
9
10
10
7
4
47
EBITDA*
-354,448
34,465
-205,149
-4,883
325,342
-194,063
-886,837
-81,352
1,223,454
* Earnings Before Interest, Tax, Depreciation and Amortisation
May 2024
May 2023
May 2022
May 2021
May 2020
May 2019
May 2018
May 2017
May 2016
Tangible Assets
46,587
57,707
87,144
136,062
192,824
218,595
84,650
38,283
26,741
Intangible Assets
12,947
14,061
15,175
16,288
17,402
18,516
19,630
Investments & Other
Debtors (Due After 1 year)
66,163
Total Fixed Assets
59,534
71,768
102,319
152,350
210,226
303,274
104,280
38,283
26,741
Stock & work in progress
Trade Debtors
836
26,988
62,912
270,375
43,125
169,834
6,733
863,580
957,105
Group Debtors
Misc Debtors
37,377
84,039
18,253
40,027
17,684
93,757
32,620
Cash
235,940
546,779
491,139
485,878
740,030
262,477
873,047
misc current assets
total current assets
274,153
657,806
572,304
796,280
800,839
526,068
912,400
863,580
957,105
total assets
333,687
729,574
674,623
948,630
1,011,065
829,342
1,016,680
901,863
983,846
Bank overdraft
Bank loan
Trade Creditors
25,280
69,227
19,824
22,379
15,509
47,621
2,279
4,452
5,083
Group/Directors Accounts
other short term finances
hp & lease commitments
other current liabilities
12,488
9,793
1,195
3,571
2,645
1,484
1,637
total current liabilities
37,768
79,020
21,019
25,950
18,154
49,105
3,916
4,452
5,083
loans
hp & lease commitments
Accruals and Deferred Income
other liabilities
provisions
total long term liabilities
total liabilities
37,768
79,020
21,019
25,950
18,154
49,105
3,916
4,452
5,083
net assets
295,919
650,554
653,604
922,680
992,911
780,237
1,012,764
897,411
978,763
total shareholders funds
295,919
650,554
653,604
922,680
992,911
780,237
1,012,764
897,411
978,763
May 2024
May 2023
May 2022
May 2021
May 2020
May 2019
May 2018
May 2017
May 2016
Operating Activities
Operating Profit
-387,181
-26,403
-273,961
-70,844
262,059
-236,785
-886,837
-81,352
1,223,454
Depreciation
31,619
59,754
67,699
64,847
62,169
41,608
Amortisation
1,114
1,114
1,113
1,114
1,114
1,114
Tax
-49,886
-244,691
Stock
Debtors
-72,814
29,862
-229,237
249,593
-268,945
290,401
-824,227
-93,525
957,105
Creditors
-43,947
49,403
-2,555
6,870
-32,112
45,342
-2,173
-631
5,083
Accruals and Deferred Income
2,695
8,598
-2,376
926
1,161
-153
1,637
Deferred Taxes & Provisions
Cash flow from operations
-322,886
62,604
19,157
-246,680
513,450
-439,275
-63,146
11,542
26,741
Investing Activities
capital expenditure
-20,499
-30,317
-18,781
-8,085
-36,398
-175,553
-65,997
-11,542
-26,741
Change in Investments
cash flow from investments
-20,499
-30,317
-18,781
-8,085
-36,398
-175,553
-65,997
-11,542
-26,741
Financing Activities
Bank loans
Group/Directors Accounts
Other Short Term Loans
Long term loans
Hire Purchase and Lease Commitments
other long term liabilities
share issue
12,000
1,000,007
interest
20,546
23,353
4,885
613
501
4,258
2,183
cash flow from financing
32,546
23,353
4,885
613
501
4,258
1,002,190
cash and cash equivalents
cash
-310,839
55,640
5,261
-254,152
477,553
-610,570
873,047
overdraft
change in cash
-310,839
55,640
5,261
-254,152
477,553
-610,570
873,047
intract pharma limited Credit Report and Business Information
Very Low Risk70 - 100
Low Risk50 - 70
Moderate Risk30 - 50
High Risk20 - 30
Very High Risk0 - 20
Get a comprehensive credit check for intract pharma limited. Get real-time insights into intract pharma limited's credit score, group structure and payment trends.
Perform a competitor analysis for intract pharma limited by selecting its closest rivals, whether from the PROFESSIONAL, SCIENTIFIC AND TECHNICAL ACTIVITIES sector, other micro companies, companies in CB22 area or any other competitors across 12 key performance metrics.
intract pharma limited Ownership
INTRACT PHARMA LIMITED group structure
Intract Pharma Limited has no subsidiary companies.
Ultimate parent company
INTRACT PHARMA LIMITED
09610219
INTRACT PHARMA LIMITED Shareholders
The largest shareholders in Intract Pharma Limited include Abdul Basit and Cycle Pharmaceuticals Limited.
abdul basit
59.05%
cycle pharmaceuticals limited
26.46%
ucl business plc
7.94%
william lindsay
6.56%
intract pharma limited directors
Intract Pharma Limited currently has 4 directors.
The longest serving directors include
Professor Syed Basit (May 2015) and
Mr James Harrison (Nov 2015).
72110 - Research and experimental development on biotechnology
incorporation date
May 2015
age
10
incorporated
UK
ultimate parent company
None
accounts
Total Exemption Full
last accounts submitted
May 2024
previous names
N/A
accountant
TAYABALI & WHITE
auditor
-
address
5 high green, great shelford, cambridge, CB22 5EG
Bank
-
Legal Advisor
-
intract pharma limited Charges & Mortgages
A charge, or mortgage, refers to the rights a company gives to a lender in return for a loan, often in the form of security given over business assets.
We did not find charges/mortgages relating to intract pharma limited.
intract pharma limited Capital Raised & Share Issues BETA
When a company issues new shares, e.g. to new investors following a funding round, it is required to notify Companies House within one month of making an allotment of shares.
Click to start generating capital raising & share issue transactions for INTRACT PHARMA LIMITED. This can take several minutes, an email will notify you when this has completed.
intract pharma limitedCompanies House Filings - See Documents
